The first human trial of an antibody therapy to treat COVID-19 is underway.
SMS-embedded video links may be a potential tool for rheumatology departments to contact patients during and after the COVID-19 pandemic.
The VA health system has stopped nearly all use of hydroxychloroquine to treat COVID-19 patients.
Use of hydroxychloroquine or chloroquine may increase the risk of ventricular arrhythmia and death in patients hospitalized.
Adults with severe chronic disease or with fair or poor general health have a higher prevalence of edentulism and severe tooth loss.
Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.
Study leads Shilpa Venkatachalam, MD, and Michael George, MD, discuss the highlights of a new initiative to track the effects of COVID-19 in autoimmune disorders.
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
The WHO has suspended use of the antimalarial drug hydroxychloroquine in a clinical trial of treatments of COVID-19 after a study revealed that patients taking the drug are at increased risk for death and serious heart problems.
Authors of this viewpoint described the current challenges in the management of cytokine storm syndromes and reviewed the safety profile of intravenous anakinra.
COVID-19 spreads swiftly between people but is not easily caught from contaminated surfaces, according to updated information from the CDC.
A EULAR task force developed recommendations for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy.
In patients with sarcoidosis, COVID-19 can increase the risk for poor outcomes and death, which has resulted in the need for additional guidance on caring for these patients during the pandemic.
A number of COVID-19 vaccines under development “look pretty promising” and one or two could be ready for large-scale testing by July.
Hydroxychloroquine does not improve outcomes in COVID-19.